Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125113 | 0.87 | HPGDS (0.62) | HPGDSF2GLAADORA3ALDH1A1 | |
| SCHEMBL5128019 | 0.84 | POLB (0.51) | ADORA2AHPGDMAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL5116652 | 0.83 | GLA (0.58) | HPGDSF2GLAL3MBTL1EGLN1 | |
| SCHEMBL5122215 | 0.82 | HTT (0.57) | HPGDSNAMPTHPGDMAPK1ALDH1A1 | |
| SCHEMBL5129242 | 0.80 | HPGDS (0.51) | HPGDSALDH1A1L3MBTL1EGLN1 | |
| SCHEMBL13728238 | 0.80 | GLA (0.52) | HPGDSGLA | |
| SCHEMBL13824294 | 0.80 | EGLN1 (0.54) | HPGDSF2ADORA2AHPGDALDH1A1 | |
| SCHEMBL5123421 | 0.80 | NPC1 (0.52) | HPGDSADORA2AADORA3HPGD | |
| SCHEMBL13728338 | 0.80 | TAOK1 (0.49) | HPGDSGLAADORA3HPGDMAPK1 | |
| SCHEMBL15522371 | 0.80 | ADORA2A (0.48) | HPGDSADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328075-B2 | Pyrimidinone compounds and methods for treating influenza | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328075-B2 | Pyrimidinone compounds and methods for treating influenza | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-05-03 | — | — | US | disclosed |
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-03-20 | — | — | US | disclosed |
| WO-2012151567-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ADA, TYMP, ITPA | HPGDS 1295/4885GRM5 1044/4885F2 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.